Myocarditis associated with immune checkpoint inhibitor therapies: diagnostic and treatment strategies
Authors:
- Марина БаллюзекМБМарина Баллюзек
- Светлана ПроценкоСПСветлана Проценко
- Вера ПотиевскаяВПВера Потиевская
Open Access
- 30 April 2023
- journal article
- research article
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 69 (2) , 219-226
Abstract
This review aims to provide information on myocarditis and inflammatory cardiomyopathies associated with immune checkpoint inhibitor (ICI) therapies. Additionally, it will present current data on strategies for diagnosis and treatment of these conditions. As immunotherapy becomes more widely used, it has revealed diverse clinical symptoms, courses, and outcomes of cardiovascular immune-related adverse events (irAEs). These range from rare but potentially life-threatening fulminant forms to mild symptomatic courses that can lead to the development of dilated cardiomyopathy, arrhythmias, and heart failure. The review discusses the risk factors and common comorbid clinical conditions of irAE-associated myocarditis, as well as severity assessment and observation algorithms. The importance of a multidisciplinary approach to managing patients with this cardiotoxic irAE is also emphasized. В обзоре представлены сведения о миокардитах и воспалительных кардиопатиях, связанных с терапией ингибиторами иммунных контрольных точек (ИКТ), имеющиеся современные данные о стратегиях их диагностики и лечения. Широкое практическое применение иммунотерапии постепенно стало выявлять разнообразную клиническую симптоматику, течение и исходы иммуноопосредованных кардиологических нежелательных явлений (иНЯ) от достаточно редких, но потенциально жизнеопасных фульминантных форм, до малосимптомных вариантов течения, которые, однако, нередко приводят к развитию дилатационной кардиопатии, аритмий и сердечной недостаточности. Рассматриваются факторы риска, частые сопутствующие клинические состояния иммуноопосредованных миокардитов, вопросы оценки степени тяжести иНЯ, алгоритмы наблюдения. Подчеркивается важность мультидисциплинарного подхода к решению проблем ведения пациентов при развитии этого кардиотоксического иНЯ.Keywords
This publication has 41 references indexed in Scilit:
- Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated MyocarditisJAMA Cardiology, 2021
- Clinical variants of myocardial involvement in COVID-19-positive patients: a cumulative experience of 2020Heart Failure Reviews, 2021
- Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicitiesAutoimmunity Reviews, 2020
- Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapyCardiovascular Pathology, 2020
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendationsAnnals of Oncology, 2020
- Viral Genome Search in Myocardium of Patients with Fulminant MyocarditisEuropean Journal of Heart Failure, 2020
- A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapiesEuropean Journal of Cancer, 2020
- Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported casesJournal of Cancer Research and Clinical Oncology, 2019
- Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature ReviewCurrent Rheumatology Reports, 2019
- SEOM clinical guidelines on cardiovascular toxicity (2018)Clinical and Translational Oncology, 2019